Promising new developments in cancer chemotherapy

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 43, Issue , 1999, Pages

  Ferrante, Karen ^a   Winograd, Benjamin ^a   Canetta, Renzo ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cytotoxics; MMPI Ras FTI; Taxanes; Vaccines

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; BMS 187447; BMS 188797; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; N,N DIETHYL 2 [4 (PHENYLMETHYL)PHENOXY]ETHAMINE HYDROCHLORIDE; PACLITAXEL; SATRAPLATIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0033025398     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051100     Document Type: Conference Paper

References (90)

1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA, Arbuck SG (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13: 2056
2. Aoyagi Y, Utsugi I, Kobunai T, Yamada Y (1998) In vitro antitumor activity of a novel quinoline derivative, TAS-103, inhibiting topoisomerase I and II. Proc Am Assoc Cancer Res 39: A557
3. Barbacid M (1987) Ras genes. Ann Rev Biochem 56: 779
4. Baxter AD, Bird J, Bhogal R, Massil T, Minton KJ, Montana J, Owen DA (1997) A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. Bioorg Med Chem Lett 7: 897
5. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405
6. Bonomi P, Kim K, Chang A, Johnson D (1996) Phase III trial comparing etoposide (E), cisplatin (C) versus taxol (T) with cisplatin G-CSF versus taxol-cisplatin in advanced nonsmall cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) Trial. Proc Am Soc Clin Oncol 15: 382 (abstract)
7. Bos JL (1989) Ras cncogenes in human cancer: a review. Cancer Res 49: 4682
8. Bosslet K, Mennel HD, Rodden F, Bauer BL, Wagner F, Altmannsberger A, Sedlacek HH, Wiegandt H (1989) Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Cancer Immunol Immunother 29: 171
9. Brandes LJ, LaBelia FS (1993) Identification of intracellular histamine receptors (Hic) that regulate cell proliferation. Adv Biosci 89: 31
10. Brandes LJ, Bracken SP (1998) The intracellular histamine antagonist, N,N-diethyl-2-[4(phenylmethyl)-phenoxy]ethanamine, HCI, may potentiate doxorubicin in the treatment of metastatic breast cancer: results of a pilot study. Breast Cancer Res Treat 49: 51
11. Brandes LJ, LaBelia FS, Warrington RC (1991) Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 83: 1329
12. Brandes LJ, McDonald KA, Bracken SP, Warrington RC (1993) Results of a human pilot study testing the hypothesis that the intracellular histamine antagonist DPPE increases the therapeutic index of doxorubicin. Adv Biosci 89: 375
13. Brandes LJ, Simons KJ, Bracken SP, Warrington RC (1994) Results of a clinical trial in humans in refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4(phenylmethyl)phenoxylethanamine, HCI in combination with various single antineoplastic agents. J Clin Oncol 12: 1281
14. Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition: a review of antitumor activity. Ann Oncol 6: 967
15. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J (1993) Association between expression of activated 72-kilo-dalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85: 574
16. Chang HR, Cordon-Cardo C, Houghton AN, Cheung NK, Brennan MF (1992) Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 70: 633
17. Chapman PB, Meyers ML, Williams L, Dantis L, Yao TJ, Israel R, Morrissey D, Hamilton WB, Houghton AN, Livingston PO (1998) Immunization of melanoma patients (pts) with a bivalent GM2/GD2 ganglioside conjugate vaccine. Proc Am Assoc Cancer Res 39: A2515 (abstract)
18. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 46: 5112
19. Davidson AH, Drummond AH, Galloway WA, Whittaker M (1997) Inhibition of matrix metalloproteinase enzymes. Chem Industry p. 258
20. DeBrabander M, Gevens G, Nuydens R, Willebrords R, De-Mey J (1981) Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 78: 5608
21. Denis LJ, Verweij J (1997) Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 15: 175
22. Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, Mignot L, Chazard M, Garet F, Onetto N, Helmann S, Pouillart P (1995) Phase III randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22(suppl 8): 33
23. DPPE Investigator Brochure (1997) Bristol-Myers Squibb Accession No. 910060959
24. Einzig AI, Wlemik PH, Sasloff J, Runowicz DC, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748
25. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Berg MEL, Kerr I, Vermerken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusioin. J Clin Oncol 12: 2654
26. Farnesyltransferase Inhibitor (BMS-214662) Investigator Brochure (1998) Bristol-Myers Squibb Accession No. 91008582
27. Feizi T (1985) Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314: 53
28. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER (1975) 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report on early findings. N Engl J Med 292: 117
29. Fisher DS, Knobf MT, Durivage HJ (eds) (1989). The cancer chemotherapy handbook, 4th edn. St. Louis: Mosby-Year Book, Inc.
30. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GPM, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Winograd B, Gallant G (1998) Phase III comparative study of high-dose cisplatin (HD-cis) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 1748A (abstract)
31. Giaccone G, Splinter TAW, Debruyne C, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. J Clin Oncol 16: 2133
32. Glavin GB, Brandes LJ (1986) Antiulcerogenic and antisecretory effects of a novel diphenylmethane derivative and antiestrogen binding site ligand. Can J Physiol Pharmacol 66: 1139
33. Hamilton WB, Helling F, Livingston PO (1993) Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin. Proc Am Assoc Cancer Res 34: Abstract 2928
34. Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167
35. Henderson IC, Harris JR (1991) Principles in the management of metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases, 2nd edn. Lippincott, Philadelphia, p 547
36. Henderson IC, Berry D, Demetri G, Cirrincione L, Goldstein L, Martino S, Ingle JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17: 390A (abstract)
37. Hoshi A, Castaner J (1998) TAS-103, antineoplastic topoisomerase I and II inhibitor. Drugs Future 23: 513
38. Ishida T, Nishio K, Arioka H, Kurokawa H, Fukumoto H, Fukuoka K, Momoto T, Tomonari A, Yokote H, Iwamoto Y, Suzuki T, Usuda J, Saijo N (1997) Cytotoxic mechanisms of a novel DNA topoisomerase I and II dual inhibitor TAS-103. Proc Am Assoc Cancer Res 38: A137 (abstract)
39. Israel RJ, Chapman P, Myers M, Hamilton WB, Chang CH, Zhan C, Morrissey D, Livingston P (1998) Phase II clinical trial of GM2-KLH/QS-21 (GMK) vaccine in patients with malignant melanoma. 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy; Abstract 322
40. Jackson JH, Cochrane CG, Boume JR, Solski PA, Buss JE, Der CJ (1990) Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87: 3042
41. JM216 Investigator Brochure (Version 2) (1998) Bristol-Myers Squibb Report Accession No.910068599
42. Jones PC, Sze LL, Llu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66: 249
43. Kelland LR, Able G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum agent. Cancer Res 53: 2581
44. Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC (1997) Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 6: 267
45. Khoo K, Brandes L, Reyno L, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E (1998) Phase II trial of DPPE and doxorubicin (DOX) chemotherapy in patients with metastatic breast cancer (BMC): A National Cancer Institute of Canada (NCIC) study. Proc Am Soc Clin Oncol 17: 583 (abstract)
46. Kim R, Rine J, Kim SH (1990) Prenylation of mammalian ras protein in xenopus oocytes. Mol Cell Biol 10: 5945
47. Kirkwood JM, Hunt Strawderman MH, Emstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alpha 2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7
48. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A (1994) Protein farnesyltransferase inhibitors block the growth of rasdependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141
49. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE, Reed E (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18
50. Kudoh K, Kikuchi Y, Hiramatsu H, Hirata J, Yamamoto K, Kita K, Nagata I (1997) Enhancement of antitumor activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl) phenoxyl ethanamine HCI in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin. Eur J Cancer 33: 122
51. Larsen AK, Grondard L, Couprie J, Desioze B, Comoe L, Jardillier JC, Riou JF (1993) The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 46: 1403
52. Levy DE, Ezrin AM (1997) Matrix metalloproteinase inhibitor drugs. Emerging Drugs 2: 205
53. Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45: 10
54. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Jones Calves M, Helling F, Ritter G, Oettgen HF, Old LJ (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036
55. Livingston PO, Zhang S, Lloyd KO (1997) Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 45: 1
56. McCormick F (1989) Ras GTPase activating protein: signal transmitter and signal terminator. Cell 56: 5
57. McGuire WP, Rowinsky EK, Rosenshein NB (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273
58. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1
59. McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR (1994) Schedule dependency of orally administered bis-acetato-ammine-dichlorocyclohexylamine-platinum (IV) (JM-216) in vivo. Cancer Res 54:4118
60. Matrix Metalloproteinase Investigator's Brochure (Version 2) (1998) Bristol-Myers Squibb Accession No. 910068930
61. Menendez AT, Raventos-Suarez C, Fairchild C, Comell L, Lee F, Smykla R, Peterson R, Kramer R (1998) Mechanism of action of DPPE, a chemosensitizing agent. Proc Am Assoc Cancer Res 39: 3462 (abstract)
62. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Lavarnisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352
63. Moertel CG, Fleming TR, Macdonald J, Haller D, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321
64. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47: 1098
65. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858
66. Nolvadex Adjuvant Trial Organisation (1985) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet i: 836
67. Nolvadex Adjuvant Trial Organisation (1988) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analysis at eight years by Nolvadex Adjuvant Trial Organisation. Br J Cancer 57: 608
68. Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Goss P, Latreille J, Lopez P, Osoba D, Rodgers A (1996) A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC): a National Cancer Institute of Canada (NCIC CTG) study. Proc Am Soc Clin Oncol 16: A59 (abstract)
69. Orr PM, O'Neill CF, Nicolson MC (1991) Platinum-resistant L1210 cell lines in new platinum drug development. In: SB Howell (ed), Platinum and other metal coordination complexes in cancer chemotherapy. New York, Plenum Publishing Co.; A69
70. Poddevin B, Riou J-F, Lavelle F, Pommier Y (1993) Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 44: 767
71. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943
72. Riou J-F, Helissey P, Grondard L, Giorgi-Renault S (1991) Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol Pharmacol 40: 699
73. Rose WC, Crosswell AR, Schurig JE, Casazza AM (1993) Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 32: 197
74. Schafer WR, Kim R, Steme R, Thorner J, Kim SH, Rine J (1989) Generic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245: 379
75. Scheithauer W, Rosen H, Kornet GV, Sebesta C, Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306: 752
76. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561
77. Schulz G, Cheresh DA, Varki MN, Yu A, Staffileno LK, Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44: 5914
78. Stewart LA, Pignon JP (1995) Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899
79. Stuart G, Bertelsen K, Mangioni C, Trope C, James K (1998) Updated analysis shows a slightly significantly improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol 17: 1394 (abstract)
80. TAS-103 Investigator's Brochure (1997) Taiho Pharmaceutical Co., Ltd.
81. Taxane Analog (BMS-184476) Investigator Brochure (1997) Bristol-Myers Squibb Accession No. 910061274
82. Taxane Analog (BMS-188797-01) Investigator Brochure (1998) Bristol-Myers Squibb Accession No. 910068570
83. Thatcher N, Ranson M, Anderson H, Burt P, Davidson N, Nicolson M, Falk S, Carmichael J, Washington T, Jeynes A (1998) Phase III study of paclitaxel (TAXOL®) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). ESMO 23rd Congress
84. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12: 1748
85. Trimble FL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck S (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405
86. Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y (1997) Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 88: 992
87. Utsugi T, Kobunai T, Aoyagi K, Aoyagi Y, Nakaoka M, Yamada Y (1997) Antitumor activity of TAS-103, a novel topoisomerase I and II inhibitor against orthotopically implanted human cancers. Proc Am Assoc Cancer Res 38: A2044 (abstract)
88. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Invest New Drugs 15: 61
89. Zeng ZS, Huang Y, Cohen AM, Guillem JG (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133
90. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: 1. Focus on gangliosides. Int J Cancer 73: 42